Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast

Next Previous
X
Search
Trial Profile

Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afimoxifene (Primary) ; Tamoxifen
  • Indications Carcinoma; Early breast cancer
  • Focus Biomarker; Pharmacodynamics

    • Most Recent Events

    • 27 Feb 2020 Planned End Date changed from 15 Jul 2019 to 15 Jul 2023.
    • 27 Feb 2020 Planned primary completion date changed from 15 Jul 2019 to 15 Jul 2022.
    • 05 Jun 2018 Since study open, 39 potential participants have been contacted, 28 did not consent for screening, 9 consented, 2 are pending consent, and 9 have started study intervention, as reported in an abstract presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top